Search Press releases Keywords From To 25 Sep 2023 UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan Read More 19 Sep 2023 UCB Provides Update on U.S. Regulatory Review of Bimekizumab Read More 15 Sep 2023 UCB receives CHMP positive opinion of zilucoplan for the treatment of adults with generalized myasthenia gravis in Europe Read More 31 Aug 2023 UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio Read More 27 Jul 2023 UCB now at the inflection point – ready to start a new phase of growth Read More 18 Jul 2023 UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa Read More Pagination First page Previous page Previous … Page 24 Page 25 Page 26 Page 27 Current page 28 Page 29 Page 30 Page 31 Page 32 … Page 28 of 60 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
